- Home
- SNDX vs AGL Comparison
SNDX vs AGL Comparison
Compare SNDX & AGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- AGL
- Stock Information
- Founded
- SNDX 2005
- AGL 2016
- Country
- SNDX United States
- AGL United States
- Employees
- SNDX N/A
- AGL N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- AGL Managed Health Care
- Sector
- SNDX Health Care
- AGL Health Care
- Exchange
- SNDX Nasdaq
- AGL Nasdaq
- Market Cap
- SNDX 1.1B
- AGL 952.1M
- IPO Year
- SNDX 2016
- AGL 2021
- Fundamental
- Price
- SNDX $9.92
- AGL $1.78
- Analyst Decision
- SNDX Strong Buy
- AGL Hold
- Analyst Count
- SNDX 11
- AGL 20
- Target Price
- SNDX $34.00
- AGL $4.41
- AVG Volume (30 Days)
- SNDX 1.7M
- AGL 2.6M
- Earning Date
- SNDX 08-04-2025
- AGL 08-05-2025
- Dividend Yield
- SNDX N/A
- AGL N/A
- EPS Growth
- SNDX N/A
- AGL N/A
- EPS
- SNDX N/A
- AGL N/A
- Revenue
- SNDX $43,722,000.00
- AGL $5,988,958,000.00
- Revenue This Year
- SNDX $431.08
- AGL N/A
- Revenue Next Year
- SNDX $105.38
- AGL $10.13
- P/E Ratio
- SNDX N/A
- AGL N/A
- Revenue Growth
- SNDX N/A
- AGL 23.07
- 52 Week Low
- SNDX $8.58
- AGL $1.50
- 52 Week High
- SNDX $23.37
- AGL $7.53
- Technical
- Relative Strength Index (RSI)
- SNDX 51.66
- AGL 28.22
- Support Level
- SNDX $9.42
- AGL $2.10
- Resistance Level
- SNDX $10.75
- AGL $2.11
- Average True Range (ATR)
- SNDX 0.58
- AGL 0.11
- MACD
- SNDX 0.08
- AGL -0.03
- Stochastic Oscillator
- SNDX 51.74
- AGL 0.56
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.